DOXORUBICIN IN RELAPSED SOFT-TISSUE SARCOMA - JUSTIFICATION OF PHASE-II EVALUATION OF NEW DRUGS IN THIS DISEASE

被引：20
作者：
BLACKLEDGE, G
VANOOSTEROM, A
MOURIDSEN, H
STEWARD, WP
BUESA, J
THOMAS, D
SYLVESTER, R
ROUESSE, J
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1990年 / 26卷 / 02期
关键词：
D O I：
10.1016/0277-5379(90)90296-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：139 / 141
页数：3
相关论文
共 5 条
[1]   RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].
BLACKLEDGE, G ;
LAWTON, F ;
REDMAN, C ;
KELLY, K .
BRITISH JOURNAL OF CANCER, 1989, 59 (04) :650-653
[2]   CYCLOPHOSPHAMIDE VERSUS IFOSFAMIDE - FINAL REPORT OF A RANDOMIZED PHASE-II TRIAL IN ADULT SOFT-TISSUE SARCOMAS [J].
BRAMWELL, VHC ;
MOURIDSEN, HT ;
SANTORO, A ;
BLACKLEDGE, G ;
SOMERS, R ;
VERWEY, J ;
DOMBERNOWSKY, P ;
ONSRUD, M ;
THOMAS, D ;
SYLVESTER, R ;
VANOOSTEROM, A .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (03) :311-321
[3]  
GOTTLIEB JA, 1975, CANCER CHEMOTH REP 3, V6, P271
[4]  
MOURIDSEN HT, 1984, ADV ANTHRACYCLINE CH, P95
[5]  
VANOOSTEROM A, 1988, RECENT CONCEPTS SARC, P183
1